Voyager Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2018. Voyager is a clinical-stage gene-therapy company developing AAV treatments for severe neurological diseases; it had no approved products and generated no product-sales revenue.
Financial performance and position
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Nine months 2017 |
|---|---|---|---|---|
| Collaboration revenue | $2.1 million | $1.1 million | $5.6 million | $3.8 million |
| Research and development expense | $16.6 million | $19.6 million | $48.0 million | $48.9 million |
| General and administrative expense | $6.6 million | $4.9 million | $25.6 million | $14.4 million |
| Net loss | $20.3 million | $23.3 million | $65.8 million | $58.9 million |
| Basic and diluted loss per share | $0.63 | $0.89 | $2.06 | $2.27 |
At September 30, cash and cash equivalents were $42.1 million and marketable debt securities were $137.5 million, or $179.6 million combined. Total assets were $197.1 million; total liabilities were $131.5 million, including $115.1 million of deferred collaboration revenue. The filing reports no interest-bearing debt. Operating lease commitments totaled $41.9 million through 2026. Accumulated deficit was $246.5 million.
For the nine months, operating cash flow was positive $8.5 million, versus cash used of $46.5 million in 2017; the improvement principally reflected the $69.0 million AbbVie upfront payment recorded through deferred revenue, not profitable operations. Investing cash flow was negative $2.2 million and financing cash flow was positive $4.3 million. Cash, cash equivalents and restricted cash increased $10.6 million to $42.9 million.
Material changes and unusual items
- Q3 net loss narrowed by $3.1 million year over year, alongside lower R&D spending and higher collaboration revenue and interest income. Nine-month net loss increased by $6.9 million, chiefly as G&A expense rose $11.2 million; that increase included $5.4 million of one-time stock compensation tied to former CEO Dr. Paul’s retirement agreement.
- R&D expense was nearly flat for the nine-month period: lower external research and manufacturing costs were largely offset by increased personnel and facility costs. G&A growth also reflected higher headcount, stock compensation, legal and intellectual-property costs.
- Voyager adopted ASC 606 in 2018. Adoption added approximately $20.0 million to deferred revenue and reduced accumulated equity through a cumulative adjustment. Under ASC 606, Q3 and nine-month 2018 collaboration revenue was respectively $1.0 million and $1.7 million lower than it would have been under ASC 605; the change affects revenue timing, not cash received.
- Stock-based compensation expense was $13.1 million for the first nine months, versus $6.9 million a year earlier.
Outlook, programs and risks
- Management estimated existing cash, cash equivalents and marketable debt securities would fund its current operating plan into early 2020. It expects substantial ongoing losses and rising expenses as clinical and preclinical programs advance; additional financing may be needed, and availability and terms are uncertain.
- VY-AADC for Parkinson’s disease was the lead clinical program. The Phase 1b study had treated 15 patients, and a separate posterior-delivery Phase 1 study had treated eight. The filing describes encouraging interim motor-function and medication-use observations, but these were from small early-stage studies and do not establish efficacy in a controlled trial.
- The planned Phase 2 VY-AADC study was designed as a randomized, placebo-surgery-controlled trial of up to 42 patients, with a 12-month primary endpoint. The filing reports an important regulatory uncertainty: an FDA addendum received in late October characterized the study as early-phase exploratory, expressed significant concern that it alone could provide substantial evidence of safety and effectiveness, and noted that two adequate and well-controlled trials are generally required. Voyager planned further FDA discussions. VY-AADC had FDA Fast Track and RMAT designations; neither assures approval.
- Voyager planned to file IND applications for its ALS and Huntington’s disease programs in 2019. VY-TAG received FDA 510(k) clearance in July 2018, but manufacturing and implementation remained in progress.
- Key risks include clinical failure or delays, uncertain regulatory requirements and trial endpoints, gene-therapy and surgical-delivery safety, manufacturing scale and comparability, reliance on third-party suppliers and collaborators, intellectual-property challenges, and the need for further capital. One Phase 1b patient experienced pulmonary embolism and related arrhythmia, attributed by investigators to immobility during the procedure; the protocol was amended to add thrombosis prophylaxis.
- No material legal proceedings or off-balance-sheet arrangements were reported. Management concluded disclosure controls were effective as of September 30, 2018.
Investor verification priorities
- Confirm cash runway against actual spending, trial costs and the timing of future collaboration payments or financing.
- Track FDA feedback on whether the VY-AADC Phase 2 results could support a BLA, and whether an additional pivotal trial will be required.
- Assess whether controlled Phase 2 results reproduce the early, small-study observations, including with the selected dose, posterior delivery route and baculovirus-produced vector.
- Review ASC 606 revenue estimates and deferred-revenue recognition, particularly changes in estimated costs and progress on collaboration work.
- Monitor AbbVie and Sanofi option decisions, collaboration performance, and delivery-device and manufacturing readiness.